If you have chosen to participate in any Molecular Haemato-oncology EQA programme except Chimerism you will receive a lyophilised cell-line/patient sample preparation for molecular analysis. Instructions for storage, reconstitution and use of the lyophilised sample will be included with the sample. Prior to reconstitution, the lyophilised cells are stable at ambient temperature however, once the cells are reconstituted they should be processed immediately.
Please note- all lyophilised samples provided within these programmes are for EQA purposes only.
If you have chosen to participate in the Chimerism programme (and in some circumstances Ig/TCR clonality trials) you will currently receive fresh blood samples. Upon receipt, these samples should be processed immediately to prevent any degradation of the DNA.
***New for 2023-2024***
As part of the continuous development of our EQA/PT provision we will be introducing several updates to our molecular haemato-oncology programmes in 2023-2024.
We will be launching a new programme, Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods (Pilot – Not Accredited) to assess laboratories’ ability to accurately detect and quantify MRD using next generation sequencing of the Immunoglobin genes.
Changes to the Measurable Residual Disease for AML by Molecular Methods Programme - Following several publications highlighting the importance of the detection of FLT3 ITD MRD in acute myeloid leukaemia, we will be including FLT3 MRD samples in the MRD for AML by Molecular Methods (Pilot – Not Accredited) programme.
Additional programme updates:
Please see programme specific pages on our website for further details.
* denotes changes to the programme in 2023/2024